July 2020 By M.Angeles Montero, BTOG Steering Committee Member From 2011 and updated in 2015, the identification of therapeutic targets for the treatment of lung cancer has resulted in the new WHO classification system for non-resection specimens, small biopsies and … Read More
February 2020 By Dr Adam Januszewski, Higher Specialty Trainee in Medical Oncology and Honorary Clinical Fellow, Imperial College London On application to medical school, lifelong learning is what I signed up to. Although at that point I wasn’t entirely sure … Read More
February 2020 By Dr Antonia Field-Smith, Consultant in Palliative Medicine, West Middlesex University Hospital Despite all the recent successes with immunotherapy, I am well aware that lung cancer remains the most common cause of cancer death in the UK. The … Read More
February 2020 By Dr Helen McDill, Respiratory Registrar and Interventional Respiratory Fellow, Derriford Hospital, Plymouth NHS Trust What a fantastic 3 days at BTOG 2020 – I have returned back to work full of ideas and enthusiasm about how to … Read More
November 2019 By Tom Newsom-Davis, BTOG Vice-Chair 1st Line Combination Immunotherapy for NSCLC: Checkmate-227 Further results from the Checkmate-227 trial were presented at ESMO 2019. Checkmate-227 is a study with multiple treatment arms, which has released results at various stages … Read More
November 2019 By Tom Newsom-Davis, BTOG Vice-Chair 1st Line Osimertinib Overall Survival Results: FLAURA The overall survival (OS) date from the FLAURA study was presented at the Presidential Session of ESMO 2019, following publication of the Progression Free Survival (PFS) … Read More
October 2019 By Tom Newsom-Davis, BTOG Vice-Chair Treatment of RET-Fusion NSCLC: LIBRETTO-001 RET fusions are found in a number of different cancer and account for approximately 2% of NSCLC. Although rare, they are predominantly found in younger patients, non-smokers or … Read More
September 2019 By Dr Matthew Callister, Consultant Respiratory Physician A year after the preliminary publication of the NELSON screening trial results at the World Conference on Lung Cancer 2018 in Toronto, low-dose CT screening was again headline news in the … Read More
March 2019 By Liz Darlison, Head of Services and Clinical Nurse Specialist for Mesothelioma UK and Professor James Spicer, BTOG Steering Committee Member. An Essential Update on mesothelioma, organised by the British Thoracic Oncology Group and Mesothelioma UK, was held … Read More
February 2019 Four first time attendees at BTOG 2019 kindly took the time to write a blog about their experience and thoughts on the conference.
December 2018 By Sanjay Agrawal, Consultant Respiratory Intensivist As specialists with an interest in thoracic oncology, we want our patients to have the best outcome whether that’s as a result of screening, early diagnosis, surgery, radiotherapy, chemotherapy or … Read More
November 2018 By Fiona McDonald, Consultant Thoracic Clinical Oncologist The plenary session at WCLC 2018 in Toronto and parallel NEJM publication bring us the eagerly awaited overall survival results from the PACIFIC trial (NCT02125461). This was a randomised double-blind … Read More
October 2018 By James Spicer, Professor of Experimental Cancer Medicine and Consultant in Medical Oncology ALTA1: brigatinib vs crizotinib in ALK-rearranged non-small cell lung cancer The initial results of this comparison of brigatinib with the first generation drug crizotinib were presented … Read More
September 2018 By Dr Matthew Callister, Consultant Respiratory Physician CT screening in Europe took a leap forward this week with the publication of the mortality results from the NELSON screening study. NELSON was a population-based controlled trial that ran in the … Read More
August 2018 By Tom Newsom-Davis, Consultant Oncologist On 26th July 2018 one of the European Medicines Agency (EMA) committees recommended that the immunotherapy drug, Durvalumab, be licensed for use in patients with locally advanced (stage III) lung cancer. Although this does not mean … Read More
July 2018 By Tom Newsom-Davis, Consultant Oncologist NICE has just approved Alectinib as first line treatment for ALK-translocated NSCLC. https://www.nice.org.uk/guidance/gid-ta10206/documents/final-appraisal-determination-document This is exciting news for patients with this comparatively rare type of lung cancer. Currently the standard of care in the … Read More